Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis

被引：2

作者：

Egan L.J. ^{[1
]}

Sandborn W.J. ^{[1
]}

机构：

[1] Department of Pharmacology, National University of Ireland, University College Hospital, Galway

来源：

Current Gastroenterology Reports | 2005年 / 7卷 / 6期

关键词：

Inflammatory Bowel Disease; Ulcerative Colitis; Infliximab; Adalimumab; Natalizumab;

D O I：

10.1007/s11894-005-0080-3

中图分类号：

学科分类号：

摘要：

Traditional medications for inflammatory bowel disease are small molecule drugs, most of which were developed for use in other diseases before being found to be efficacious for the treatment of ulcerative colitis or Crohn's disease. Recently, several exciting alternative approaches to the medical treatment of inflammatory bowel disease have been developed. These include biologic, probiotic, and apheresis therapies that offer certain advantages over traditional drug therapy for inflammatory bowel disease. The purpose of this review is to assess the current state of knowledge about novel biologic, probiotic, and apheresis therapies and to analyze how best to incorporate these therapies into evolving management paradigms of inflammatory bowel disease. Copyright © 2005 by Current Science Inc.

引用

页码：485 / 491

页数：6

共 61 条

[1]

Sandborn W.J., Hanauer S.B., Katz S., Et al., Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial, Gastroenterology, 121, pp. 1088-1094, (2001)

[2]

Rutgeerts P., Fedorak R.N., Rachmilevich D., Et al., Onercept (recombinant human p55 tumour necrosis factor receptor) treatment in patients with active Crohn's disease: Randomized, placebo-controlled, dose-finding phase II study, Gut, 53, SUPPL. VI, (2004)

[3]

Hanauer S.B., Feagan B.G., Lichtenstein G.R., Et al., Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial, Lancet, 359, pp. 1541-1549, (2002)

[4]

Targan S.R., Hanauer S.B., van Deventer S.J., Et al., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease, N Engl J Med, 337, pp. 1029-1035, (1997)

[5]

Hanauer S., Lukas M., MacIntosh D., Et al., A randomized, double-blind, placebo-controlled trial of the human anti-TNF-a monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease, Gastroenterology, 127, (2004)

[6]

Rutgeerts P., Colombel J., Enns R., Et al., Subanalyses from a phase 3 study on the evaluation of natalizumab in active Crohn's disease therapy-I (ENACT-1), Gut, 52, SUPPL., (2003)

[7]

Sandborn W.J., Hanauer S.B., Lukas M., Et al., Maintenance of remission over 1 year in patients with active Crohn's disease treated with adalimumab: Results of a blinded placebo-controlled trial, Am J Gastroenterol, (2005)

[8]

Present D.H., Rutgeerts P., Targan S., Et al., Infliximab for the treatment of fistulas in patients with Crohn's disease, N Engl J Med, 340, pp. 1398-1405, (1999)

[9]

Sands B.E., Anderson F.H., Bernstein C.N., Et al., Infliximab maintenance therapy for fistulizing Crohn's disease, N Engl J Med, 350, pp. 876-885, (2004)

[10]

Ricart E., Panaccione R., Loftus E.V., Et al., Successful management of Crohn's disease of the ileoanal pouch with infliximab, Gastroenterology, 117, pp. 429-432, (1999)

← 1 2 3 4 5 6 7 →